These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8493431)

  • 1. Data monitoring boards in the pharmaceutical industry.
    Herson J
    Stat Med; 1993 Mar; 12(5-6):555-61; discussion 563. PubMed ID: 8493431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of clinical trials and interim analyses from a drug sponsor's point of view.
    Williams GW; Davis RL; Getson AJ; Gould AL; Hwang IK; Matthews H; Shih WJ; Snapinn SM; Walton-Bowen KL
    Stat Med; 1993 Mar; 12(5-6):481-92. PubMed ID: 8493426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations.
    Rockhold FW; Enas GG
    Stat Med; 1993 Mar; 12(5-6):471-9. PubMed ID: 8493425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical issues in data monitoring of clinical trials: summary of responses to a questionnaire at NIH.
    Geller NL; Stylianou M
    Stat Med; 1993 Mar; 12(5-6):543-51; discussion 553. PubMed ID: 8493430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data monitoring committees for multicenter clinical trials sponsored by the National Institutes of Health. I. Roles and membership of data monitoring committees for trials sponsored by the National Eye Institute.
    Hawkins BS
    Control Clin Trials; 1991 Jun; 12(3):424-37. PubMed ID: 1651212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of monitoring practices in cancer clinical trials.
    George SL
    Stat Med; 1993 Mar; 12(5-6):435-50. PubMed ID: 8493422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM
    Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of clinical trials: issues and recommendations.
    Fleming TR; DeMets DL
    Control Clin Trials; 1993 Jun; 14(3):183-97. PubMed ID: 8339549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases.
    Ellenberg SS; Myers MW; Blackwelder WC; Hoth DF
    Stat Med; 1993 Mar; 12(5-6):461-7; discussion 469. PubMed ID: 8493424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of NIH- and industry-sponsored head and neck cancer clinical trials.
    Devaiah A; Murchison C
    Laryngoscope; 2016 Sep; 126(9):E300-3. PubMed ID: 27010965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data monitoring committees for Southwest Oncology Group clinical trials.
    Green S; Crowley J
    Stat Med; 1993 Mar; 12(5-6):451-5. PubMed ID: 8493423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010.
    Califf RM; Zarin DA; Kramer JM; Sherman RE; Aberle LH; Tasneem A
    JAMA; 2012 May; 307(17):1838-47. PubMed ID: 22550198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
    DeMets DL; Fleming TR; Whitley RJ; Childress JF; Ellenberg SS; Foulkes M; Mayer KH; O'Fallon J; Pollard RB; Rahal JJ
    Control Clin Trials; 1995 Dec; 16(6):408-21. PubMed ID: 8720018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current issues surrounding women and minorities in drug trials.
    Wermeling DP; Selwitz AS
    Ann Pharmacother; 1993; 27(7-8):904-11. PubMed ID: 8364277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data monitoring committees: the moral case for maximum feasible independence.
    Walters L
    Stat Med; 1993 Mar; 12(5-6):575-80; discussion 581-2. PubMed ID: 8493433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.
    Coffey CS; Levin B; Clark C; Timmerman C; Wittes J; Gilbert P; Harris S
    Clin Trials; 2012 Dec; 9(6):671-80. PubMed ID: 23250942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large clinical trials in epilepsy: funding by the NIH versus pharmaceutical industry.
    Privitera M
    Epilepsy Res; 2006 Jan; 68(1):52-6. PubMed ID: 16377139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Industry-corrupted psychiatric trials.
    Amsterdam JD; McHenry LB; Jureidini JN
    Psychiatr Pol; 2017 Dec; 51(6):993-1008. PubMed ID: 29432499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.